A study presented at the American College of Allergy, Asthma & Immunology meeting reports that 39.3% of pediatric biologic prescriptions requiring prior authorization were denied by insurance payors. The analysis focused on access barriers in pediatric care, quantifying how payer decisions can interrupt continuity for specialty therapies. For biotech companies and patient-assistance stakeholders, the data underscore that real-world adoption depends not just on clinical value but also on formulary and authorization pathways.